Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.

Zhang, Yongchang; Zeng, Liang; Zhang, Xiangyu; Li, Yizhi; Liu, Lingli; Xu, Qinqin; Yang, Haiyan; Jiang, Wenjuan; Lizaso, Analyn; Qiu, Luting; Hou, Ting; Liu, Jun; Peng, Ling; Yang, Nong

Zhang, Yongchang; Zeng, Liang; Zhang, Xiangyu; Li, Yizhi; Liu, Lingli; Xu, Qinqin; Yang, Haiyan; Jiang, Wenjuan; Lizaso, Analyn; Qiu, Luting; Hou, Ting; Liu, Jun; Peng, Ling; Yang, Nong.

Afiliação

Zhang Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. zhangyongchang@csu.edu.cn.
Zeng L; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. zhangyongchang@csu.edu.cn.
Zhang X; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China. zhangyongchang@csu.edu.cn.
Li Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Liu L; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xu Q; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Yang H; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Jiang W; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Lizaso A; Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, 810000, China.
Qiu L; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Hou T; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Liu J; Burning Rock Biotech, Guangzhou, 510300, China.
Peng L; Burning Rock Biotech, Guangzhou, 510300, China.
Yang N; Burning Rock Biotech, Guangzhou, 510300, China.

BMC Med ; 19(1): 245, 2021 10 19.

Article em En | MEDLINE | ID: mdl-34663309

Assuntos

Carcinoma Pulmonar de Células não Pequenas; Neoplasias Pulmonares; Bevacizumab; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Carcinoma Pulmonar de Células não Pequenas/genética; Receptores ErbB/genética; Humanos; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/genética; Mutação; Nomogramas; Inibidores de Proteínas Quinases/uso terapêutico

Palavras-chave

Advanced NSCLC; Bevacizumab combined with EGFR-TKI; Clinical features; Molecular features; Prediction Model

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google